EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report

Lung Cancer. 2024 Aug:194:107869. doi: 10.1016/j.lungcan.2024.107869. Epub 2024 Jul 1.

Abstract

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.

Keywords: Autoimmune factor V deficiency; Coagulation abnormalities; Epidermal growth factor receptor-tyrosine kinase inhibitor; Steroid therapy.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides* / adverse effects
  • Acrylamides* / therapeutic use
  • Adenocarcinoma of Lung / drug therapy
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Aged
  • Aniline Compounds* / adverse effects
  • Aniline Compounds* / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • ErbB Receptors* / genetics
  • Factor V Deficiency* / genetics
  • Female
  • Humans
  • Indoles
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Staging
  • Protein Kinase Inhibitors* / adverse effects
  • Protein Kinase Inhibitors* / therapeutic use
  • Pyrimidines

Substances

  • Protein Kinase Inhibitors
  • ErbB Receptors
  • osimertinib
  • Acrylamides
  • Aniline Compounds
  • EGFR protein, human
  • Antineoplastic Agents
  • Indoles
  • Pyrimidines